What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist

Sassine Ghanem,1 Sandy El Bitar,1 Sami Hossri,1 Chanudi Weerasinghe,2 Jean Paul Atallah2 1Department of Internal Medicine, 2Department of Hematology and Oncology, Staten Island University Hospital – Northwell Health, New York, NY, USA Abstract: Lung cancer remains the leading cause of death in cance...

Full description

Bibliographic Details
Main Authors: Ghanem S, El Bitar S, Hossri S, Weerasinghe C, Atallah JP
Format: Article in Journal/Newspaper
Language:English
Published: Dove Medical Press 2017
Subjects:
Online Access:https://doaj.org/article/f36465fd5781423c959328902d41a059
id ftdoajarticles:oai:doaj.org/article:f36465fd5781423c959328902d41a059
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:f36465fd5781423c959328902d41a059 2023-05-15T18:13:07+02:00 What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist Ghanem S El Bitar S Hossri S Weerasinghe C Atallah JP 2017-07-01T00:00:00Z https://doaj.org/article/f36465fd5781423c959328902d41a059 EN eng Dove Medical Press https://www.dovepress.com/what-we-know-about-surgical-therapy-in-early-stage-non-small-cell-lung-peer-reviewed-article-CMAR https://doaj.org/toc/1179-1322 1179-1322 https://doaj.org/article/f36465fd5781423c959328902d41a059 Cancer Management and Research, Vol Volume 9, Pp 267-278 (2017) Segmentectomy – Wedge Resection – Lung Cancer – Lobectomy – Non-small cell lung cancer- Sublobar resection Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 article 2017 ftdoajarticles 2022-12-31T13:38:07Z Sassine Ghanem,1 Sandy El Bitar,1 Sami Hossri,1 Chanudi Weerasinghe,2 Jean Paul Atallah2 1Department of Internal Medicine, 2Department of Hematology and Oncology, Staten Island University Hospital – Northwell Health, New York, NY, USA Abstract: Lung cancer remains the leading cause of death in cancer patients. The gold standard for the treatment of early-stage non-small-cell lung cancer is lobectomy with mediastinal lymph-node dissection or systematic lymph-node sampling. The evidence behind this recommendation is based on the sole randomized controlled trial conducted to date, done by the Lung Cancer Study Group and published in 1995, which found a superiority for lobectomy over sublobar resection with regard to local recurrence rate and improved survival. The population studied at that time were medically fit patients at low risk for surgery with a stage IA non-small-cell lung carcinoma, ie, a solitary tumor less than 3 cm in size. In practice, however, thoracic surgeons have continued to push the limit of a more conservative surgical resection in this patient population. Since then, several retrospective studies have attempted to identify the ideal population to benefit from sublobar resection without it affecting survival or local recurrence. Several variables have been studied, including tumor size, patient age, surgical approach, histological and radiological properties, and optimal surgical resection margin, as well as promising prognostic biomarkers. In this review, we summarize the data available in the literature regarding the surgical approach to patients with stage IA non-small-cell lung cancer studying all the aforementioned variables. Keywords: segmentectomy, wedge resection, lung cancer, lobectomy, non-small-cell lung cancer, sublobar resection Article in Journal/Newspaper sami Directory of Open Access Journals: DOAJ Articles
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic Segmentectomy – Wedge Resection – Lung Cancer – Lobectomy – Non-small cell lung cancer- Sublobar resection
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle Segmentectomy – Wedge Resection – Lung Cancer – Lobectomy – Non-small cell lung cancer- Sublobar resection
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Ghanem S
El Bitar S
Hossri S
Weerasinghe C
Atallah JP
What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
topic_facet Segmentectomy – Wedge Resection – Lung Cancer – Lobectomy – Non-small cell lung cancer- Sublobar resection
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
description Sassine Ghanem,1 Sandy El Bitar,1 Sami Hossri,1 Chanudi Weerasinghe,2 Jean Paul Atallah2 1Department of Internal Medicine, 2Department of Hematology and Oncology, Staten Island University Hospital – Northwell Health, New York, NY, USA Abstract: Lung cancer remains the leading cause of death in cancer patients. The gold standard for the treatment of early-stage non-small-cell lung cancer is lobectomy with mediastinal lymph-node dissection or systematic lymph-node sampling. The evidence behind this recommendation is based on the sole randomized controlled trial conducted to date, done by the Lung Cancer Study Group and published in 1995, which found a superiority for lobectomy over sublobar resection with regard to local recurrence rate and improved survival. The population studied at that time were medically fit patients at low risk for surgery with a stage IA non-small-cell lung carcinoma, ie, a solitary tumor less than 3 cm in size. In practice, however, thoracic surgeons have continued to push the limit of a more conservative surgical resection in this patient population. Since then, several retrospective studies have attempted to identify the ideal population to benefit from sublobar resection without it affecting survival or local recurrence. Several variables have been studied, including tumor size, patient age, surgical approach, histological and radiological properties, and optimal surgical resection margin, as well as promising prognostic biomarkers. In this review, we summarize the data available in the literature regarding the surgical approach to patients with stage IA non-small-cell lung cancer studying all the aforementioned variables. Keywords: segmentectomy, wedge resection, lung cancer, lobectomy, non-small-cell lung cancer, sublobar resection
format Article in Journal/Newspaper
author Ghanem S
El Bitar S
Hossri S
Weerasinghe C
Atallah JP
author_facet Ghanem S
El Bitar S
Hossri S
Weerasinghe C
Atallah JP
author_sort Ghanem S
title What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
title_short What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
title_full What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
title_fullStr What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
title_full_unstemmed What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
title_sort what we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/f36465fd5781423c959328902d41a059
genre sami
genre_facet sami
op_source Cancer Management and Research, Vol Volume 9, Pp 267-278 (2017)
op_relation https://www.dovepress.com/what-we-know-about-surgical-therapy-in-early-stage-non-small-cell-lung-peer-reviewed-article-CMAR
https://doaj.org/toc/1179-1322
1179-1322
https://doaj.org/article/f36465fd5781423c959328902d41a059
_version_ 1766185593757237248